If you have been reading about incretin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
In Quercus ilex oaks, the fungus neutralizes harmful compounds from the tree's own leaf litter and transfer the nutrients back to the tree through the roots - an essential step for making certain growing conditions possible for these oaks. Another study shows that P.arhizus aided White Cover (Trifolium repens) growth in contaminated mining soils, and improved the growth as well as the mercury tolerance in these flowers by substantial amounts.
Radioactive decay (also known as nuclear decay, radioactivity, radioactive disintegration, or nuclear disintegration) is the process by which an unstable atomic nucleus loses energy by radiation. A material containing unstable nuclei is considered radioactive. Three of the most common types of decay are alpha, beta, and gamma decay. The weak force is the mechanism that is responsible for beta decay, while the other two are governed by the electromagnetic and nuclear forces. Radioactive decay is a random process at the level of single atoms. According to quantum theory, it is impossible to predict when a particular atom will decay, regardless of how long the atom has existed. However, for a significant number of identical atoms, the overall decay rate can be expressed as a decay constant or as a half-life. The half-lives of radioactive isotopes have a huge range: from nearly instantaneous to far longer than the age of the universe. The decaying nucleus is called the parent radionuclide (or parent radioisotope), and the process produces at least one daughter nuclide. Except for gamma decay or internal conversion from a nuclear excited state, the decay is a nuclear transmutation resulting in a daughter containing a different number of protons or neutrons (or both). When the number of protons changes, an atom of a different chemical element is created. There are 28 naturally occurring chemical elements on Earth that are radioactive, consisting of 35 radionuclides (seven elements have two different radionuclides each) that date before the time of formation of the Solar System.
In 2000, the World Health Organization redefined "carcinoid", but this new definition has not been accepted by all practitioners. This has led to some complexity in distinguishing between carcinoid and other neuroendocrine tumors in the literature. According to the American Cancer Society, the 2000 WHO definition states: The WHO now divides these growths into neuroendocrine tumors and neuroendocrine cancers. Neuroendocrine tumors are growths that look benign but that might possibly be able to spread to other parts of the body. Neuroendocrine cancers are abnormal growths of neuroendocrine cells which can spread to other parts of the body.
=== Secretariat === The commission is serviced by a Secretariat headed by a Secretary with four Additional Secretaries, several Joint Secretaries, Deputy Secretaries, and other supporting staff. The secretariat, for administrative purposes, is further divided into divisions, each undertaking having a specific responsibility:
Sources: en.wikipedia.org
In November 1917, after learning of the uprising in Petrograd (now called Saint Petersburg), Moscow's Bolsheviks started an uprising. On 2 November [O.S. 15 November] 1917, after heavy fighting, Soviet power was established in Moscow. Vladimir Lenin, fearing invasion, moved the state's capital back to Moscow on 12 March 1918. The Kremlin once again became the seat of power, the political center of the new state. With the change in societal values imposed by communist ideology, the tradition of preserving cultural heritage was broken. Independent preservation societies, even those that defended only secular landmarks, were disbanded by the end of the 1920s. A new anti-religious campaign, launched in 1929, coincided with the collectivization of peasants; the destruction of churches in cities peaked around 1932. In 1937, letters were written to the Central Committee of the Communist Party of the Soviet Union to rename Moscow to "Stalindar" or "Stalinodar". Stalin rejected this suggestion. During World War II, the State Defense Committee and the General Staff of the Red Army were located in Moscow. In 1941, 16 divisions of the national volunteers (more than 160,000 people), 25 battalions, and 4 engineering regiments were formed among Muscovites. Between October 1941 and January 1942, the German Army Group Centre was stopped at the outskirts of the city, and then repelled in the Battle of Moscow. Many factories were evacuated, together with much of the government, and from 20 October the city was declared to be under siege.
== Allergies == Plantain and banana allergies occur with typical characteristics of food allergy or latex fruit syndrome, including itching and mild swelling of the lips, tongue, palate or throat, skin rash, stomach complaints or anaphylactic shock. Among more than 1000 proteins identified in Musa species were numerous previously described protein allergens.
Richard Carthew et al. state in their 2004 study of siRNA/miRNA silencing pathways in Drosophila that siRNA-induced post-transcriptional gene silencing is initiated by the assembly of the RNA-induced silencing complex (RISC). RISC silences expression of certain genes by cleaving the mRNA molecules coding those genes. To begin the process in that system, they state that one of the two siRNA strands, the anti-sense guide strand, is loaded into the RISC while the other strand, the sense passenger strand, is degraded; they go on to state that certain Drosophila Dicer enzymes may be responsible for loading the guide strand into RISC. Then, in a perspective from 2009, the view is offered that "siRNA scans for and directs RISC" to a perfectly complementary sequence on the mRNA molecules. The cleavage of the mRNA molecules is thought to be catalyzed by the Piwi domain of Argonaute proteins of the RISC; the mRNA molecule is then cut precisely by cleaving the phosphodiester bond between the target nucleotides which are paired to siRNA residues 10 and 11, counting from the 5'end. As Orban and Izaurralde note with regard to a further study in Drosophila cells, "[f]ollowing this initial endonucleolytic cleavage, the mRNA is [further] degraded" by cellular exonucleases; they show that in this system, the 5' fragments "are rapidly degraded from their 3' ends by the exosomes, whereas the 3' fragments are degraded from their 5' ends by XRN1", a 5'-3' exoribonuclease.
== Signs and symptoms == Symptoms of bone sarcomas typically include bone pain, especially at night, and swelling around the site of the tumor. Symptoms of soft-tissue sarcomas vary, but they often present as firm, oftentimes painless lumps or nodules. Gastrointestinal stromal tumors (GIST, a subtype of soft-tissue sarcoma) often are asymptomatic, but can be associated with vague complaints of abdominal pain, bleeding into the intestines, a feeling of fullness, or other signs of intestinal obstruction.
=== Histology === In staining during microscopic examination for diagnosis or research, acid dyes are used to color basic tissue proteins. In contrast, basic dyes are used to stain cell nuclei and some other acidic components of tissues. Regarding cellular structures, acid dyes will stain acidophilic structures that have a net positive charge due to the fact that they have a negatively charged chromophore. Acidophilic structures include the cytoplasm, collagen and mitochondria. The two have an affinity for each other due to the conflicting charges. Examples of acid dyes used in medicine include:
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。